432 related articles for article (PubMed ID: 17363537)
1. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.
Small EJ; Tchekmedyian NS; Rini BI; Fong L; Lowy I; Allison JP
Clin Cancer Res; 2007 Mar; 13(6):1810-5. PubMed ID: 17363537
[TBL] [Abstract][Full Text] [Related]
2. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy.
O'Mahony D; Morris JC; Quinn C; Gao W; Wilson WH; Gause B; Pittaluga S; Neelapu S; Brown M; Fleisher TA; Gulley JL; Schlom J; Nussenblatt R; Albert P; Davis TA; Lowy I; Petrus M; Waldmann TA; Janik JE
Clin Cancer Res; 2007 Feb; 13(3):958-64. PubMed ID: 17289891
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
Ansell SM; Hurvitz SA; Koenig PA; LaPlant BR; Kabat BF; Fernando D; Habermann TM; Inwards DJ; Verma M; Yamada R; Erlichman C; Lowy I; Timmerman JM
Clin Cancer Res; 2009 Oct; 15(20):6446-53. PubMed ID: 19808874
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Madan RA; Mohebtash M; Arlen PM; Vergati M; Rauckhorst M; Steinberg SM; Tsang KY; Poole DJ; Parnes HL; Wright JJ; Dahut WL; Schlom J; Gulley JL
Lancet Oncol; 2012 May; 13(5):501-8. PubMed ID: 22326924
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Canil CM; Moore MJ; Winquist E; Baetz T; Pollak M; Chi KN; Berry S; Ernst DS; Douglas L; Brundage M; Fisher B; McKenna A; Seymour L
J Clin Oncol; 2005 Jan; 23(3):455-60. PubMed ID: 15659491
[TBL] [Abstract][Full Text] [Related]
6. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
Phan GQ; Weber JS; Sondak VK
Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P; Hamid O; O'Day S
Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
[TBL] [Abstract][Full Text] [Related]
8. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
Beck KE; Blansfield JA; Tran KQ; Feldman AL; Hughes MS; Royal RE; Kammula US; Topalian SL; Sherry RM; Kleiner D; Quezado M; Lowy I; Yellin M; Rosenberg SA; Yang JC
J Clin Oncol; 2006 May; 24(15):2283-9. PubMed ID: 16710025
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer.
Theoret MR; Arlen PM; Pazdur M; Dahut WL; Schlom J; Gulley JL
Clin Genitourin Cancer; 2007 Jun; 5(5):347-50. PubMed ID: 17645835
[No Abstract] [Full Text] [Related]
10. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer.
Thompson RH; Allison JP; Kwon ED
Urol Oncol; 2006; 24(5):442-7. PubMed ID: 16962497
[TBL] [Abstract][Full Text] [Related]
11. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
Weber J
Oncologist; 2007 Jul; 12(7):864-72. PubMed ID: 17673617
[TBL] [Abstract][Full Text] [Related]
12. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer.
Klyushnenkova EN; Riabov VB; Kouiavskaia DV; Wietsma A; Zhan M; Alexander RB
Prostate; 2014 Oct; 74(14):1423-32. PubMed ID: 25111463
[TBL] [Abstract][Full Text] [Related]
13. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
Maker AV; Phan GQ; Attia P; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Haworth LR; Levy C; Kleiner D; Mavroukakis SA; Yellin M; Rosenberg SA
Ann Surg Oncol; 2005 Dec; 12(12):1005-16. PubMed ID: 16283570
[TBL] [Abstract][Full Text] [Related]
14. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
Fong L; Kwek SS; O'Brien S; Kavanagh B; McNeel DG; Weinberg V; Lin AM; Rosenberg J; Ryan CJ; Rini BI; Small EJ
Cancer Res; 2009 Jan; 69(2):609-15. PubMed ID: 19147575
[TBL] [Abstract][Full Text] [Related]
15. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
van den Eertwegh AJ; Versluis J; van den Berg HP; Santegoets SJ; van Moorselaar RJ; van der Sluis TM; Gall HE; Harding TC; Jooss K; Lowy I; Pinedo HM; Scheper RJ; Stam AG; von Blomberg BM; de Gruijl TD; Hege K; Sacks N; Gerritsen WR
Lancet Oncol; 2012 May; 13(5):509-17. PubMed ID: 22326922
[TBL] [Abstract][Full Text] [Related]
16. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
Carthon BC; Wolchok JD; Yuan J; Kamat A; Ng Tang DS; Sun J; Ku G; Troncoso P; Logothetis CJ; Allison JP; Sharma P
Clin Cancer Res; 2010 May; 16(10):2861-71. PubMed ID: 20460488
[TBL] [Abstract][Full Text] [Related]
17. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
O'Day SJ; Hamid O; Urba WJ
Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
[TBL] [Abstract][Full Text] [Related]
18. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
Fong L; Small EJ
J Clin Oncol; 2008 Nov; 26(32):5275-83. PubMed ID: 18838703
[TBL] [Abstract][Full Text] [Related]
19. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.
Small EJ; McMillan A; Meyer M; Chen L; Slichenmyer WJ; Lenehan PF; Eisenberger M
J Clin Oncol; 2001 Mar; 19(5):1304-11. PubMed ID: 11230472
[TBL] [Abstract][Full Text] [Related]
20. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management.
Movva S; Verschraegen C
Expert Opin Biol Ther; 2009 Feb; 9(2):231-41. PubMed ID: 19236253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
